These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9161312)

  • 21. Withdrawal after discontinuation of paroxetine.
    Arya DK
    Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183
    [No Abstract]   [Full Text] [Related]  

  • 22. [A case of probable neuroleptic malignant syndrome induced by monotherapy with paroxetine].
    Nishimura H; Kashima N
    Seishin Shinkeigaku Zasshi; 2004; 106(6):723-6. PubMed ID: 15387267
    [No Abstract]   [Full Text] [Related]  

  • 23. Pruritus induced by interruption of paroxetine therapy.
    Mazzatenta C; Peonia G; Martini P
    Br J Dermatol; 2004 Apr; 150(4):787. PubMed ID: 15099390
    [No Abstract]   [Full Text] [Related]  

  • 24. Reversible paroxetine-induced symptomatic hypothyroidism.
    Takahashi M; Sawayama E; Sawayama T; Miyaoka H
    Pharmacopsychiatry; 2007 Sep; 40(5):201-2. PubMed ID: 17874352
    [No Abstract]   [Full Text] [Related]  

  • 25. Digitalis intoxication induced by paroxetine co-administration.
    Yasui-Furukori N; Kaneko S
    Lancet; 2006 Mar; 367(9512):788. PubMed ID: 16517279
    [No Abstract]   [Full Text] [Related]  

  • 26. Manufacturer admits increase in suicidal behaviour in patients taking paroxetine.
    Lenzer J
    BMJ; 2006 May; 332(7551):1175. PubMed ID: 16709983
    [No Abstract]   [Full Text] [Related]  

  • 27. Putting GlaxoSmithKline to the test over paroxetine.
    Doshi P
    BMJ; 2013 Nov; 347():f6754. PubMed ID: 24222673
    [No Abstract]   [Full Text] [Related]  

  • 28. A review of the psychomotor effects of paroxetine.
    Hawley CJ; McPhee S; Quick SJ; Smith VR
    Int Clin Psychopharmacol; 1997 Jan; 12(1):13-8. PubMed ID: 9179629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive Donepezil for Anxiety Symptoms With Poor Response to Paroxetine in a Patient With Probable Mild Cognitive Impairment.
    Chu CW; Liang CS; Wan FJ
    Clin Neuropharmacol; 2018; 41(6):236-237. PubMed ID: 30273190
    [No Abstract]   [Full Text] [Related]  

  • 30. Visual and auditory hallucinations during normal use of paroxetine for treatment of major depressive disorder.
    Monji A; Kato T; Mizoguchi Y; Horikawa H; Seki Y; Kanba S
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E14-5. PubMed ID: 22231326
    [No Abstract]   [Full Text] [Related]  

  • 31. [Narcoleptic syndrome as a possible side effect of paroxetine].
    Alonso H; Ortí-Pareja M; Jiménez-Jiménez FJ
    Rev Neurol; 2004 Dec 1-15; 39(11):1092. PubMed ID: 15597274
    [No Abstract]   [Full Text] [Related]  

  • 32. Stopping the pills.
    van der Cammen TJ; Tanis AA; Maes RM; de Man RA
    Lancet; 1999 Aug; 354(9178):564. PubMed ID: 10470702
    [No Abstract]   [Full Text] [Related]  

  • 33. [Three cases of intestinal inflammatory disease caused by anti-depressant treatment with paroxetine].
    Torras Bernáldez MT; Pardo Fontfria C; Bernad Gimeno JA; Roig Grau I; Pedregosa Dueñas MM; Plans Soriano E
    Aten Primaria; 2003 Feb; 31(2):135. PubMed ID: 12609115
    [No Abstract]   [Full Text] [Related]  

  • 34. Bilateral angle closure glaucoma and visual loss precipitated by antidepressant and antianxiety agents in a patient with depression.
    Kadoi C; Hayasaka S; Tsukamoto E; Matsumoto M; Hayasaka Y; Nagaki Y
    Ophthalmologica; 2000; 214(5):360-1. PubMed ID: 10965252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paroxetine withdrawal syndrome in a neonate.
    Dahl ML; Olhager E; Ahlner J
    Br J Psychiatry; 1997 Oct; 171():391-2. PubMed ID: 9373435
    [No Abstract]   [Full Text] [Related]  

  • 36. Fibrosing omental panniculitis and polyserositis associated with long-term treatment by paroxetine.
    Rozin A; Bishara B; Ben-Izhak O; Fischer D; Carter A; Edoute Y
    Isr Med Assoc J; 2000 Sep; 2(9):714-6. PubMed ID: 11062779
    [No Abstract]   [Full Text] [Related]  

  • 37. Cutaneous vasculitis induced by paroxetine.
    Margolese HC; Chouinard G; Beauclair L; Rubino M
    Am J Psychiatry; 2001 Mar; 158(3):497. PubMed ID: 11230000
    [No Abstract]   [Full Text] [Related]  

  • 38. Paroxetine may increase risk for congenital malformations.
    Cuzzell JZ
    Dermatol Nurs; 2006 Feb; 18(1):68. PubMed ID: 16617525
    [No Abstract]   [Full Text] [Related]  

  • 39. Paroxetine-Related Adult-Onset Tic Disorder: A Presentation of Primary Progressive Multiple Sclerosis.
    Mendonça MD; Leitão C; Barahona-Corrêa B; Lampreia T
    J Neuropsychiatry Clin Neurosci; 2015; 27(3):e214-5. PubMed ID: 26222974
    [No Abstract]   [Full Text] [Related]  

  • 40. Hair loss associated with paroxetine treatment: a case report.
    Zalsman G; Sever J; Munitz H
    Clin Neuropharmacol; 1999; 22(4):246-7. PubMed ID: 10442258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.